Login to Your Account

Immunomedics Reports High Efficacy for Epratuzumab Phase II

By Catherine Shaffer
Staff Writer

Wednesday, August 14, 2013
Immunomedics Inc.'s epratuzumab exceeded expectations in a Phase II trial in follicular lymphoma, producing a response rate of 88.2 percent when used in combination with rituximab.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription